Госпитализация в Москве
Вики-госпиталь - главная ›› На русском ›› "Похудательная" вакцина уже проходит испытания на людях

1 2 

A 1998 rat study showed that continuous GLP-1 infusion to the third ventricle over a six day period only provided appetite control on day 1. There was partial reduction on day 2, and no effect on appetite thereafter. Further, none of the rats experienced any weight loss. Researchers in the rat study concluded that GLP-1 was not a long-term regulator of caloric intake and body weight in the central nervous system (CNS). 2 Whether this proves to be true in humans, remains to be seen.

Dr. Joel Habener of Harvard University says that an oral formulation of GLP-1 could be made available within two to three years. At that time, long term study on appetite suppression in humans can be conducted.

  • Flint A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. (medline) J Clin Invest. 1998 Feb 1; 101(3): 515-520.
  1. Toft-Nielsen MB, et al. Iv glucagon-like peptide-1 (GLP-1) lowers blood glucose levels in NIDDM patients regardless of fasting glucose, BMI, and insulin capacity. Diabetes 46(Suppl. 1):A189.
  2. Donahey JCK, et al. Intraventricular GLP-1 reduces short- but not long-term food intake or


1 2 

Вакцина против ожирения
Чудодейственную вакцину разработали скандинавские ученые.